Linda Stein Gold, MD, and Matthew Zirwas, MD, provide a discussion on the role of JAK inhibitors in inflammatory diseases.
EP. 1: An Overview of JAK Inhibitors
Linda Stein Gold, MD, provides an overview of the four JAK inhibitors currently available for treating inflammatory diseases.
EP. 2: Safety and Efficacy of JAK Inhibitors
Key opinion leaders explain the box warnings and safety profiles of JAK inhibitors.
EP. 3: Reviewing Clinical Trial Data for JAK Inhibitors
Matthew Zirwas, MD, breaks down the safety of JAK inhibitors based on clinical trial data.
EP. 4: Risk of Systemic Absorption with JAK Inhibitors
Clinicians provide insight into the risk of high systemic absorption levels with JAK inhibitor treatments.
EP. 5: Treating Atopic Dermatitis with Ruxolitinib
Dr Matthew Zirwas describes his experience using JAK inhibitor ruxolitinib in his clinical practice.
EP. 6: Advice for Clinicians on JAK Inhibitors
Linda Stein Gold, MD, and Matthew Zirwas, MD, share some advice for clinicians on how to discuss JAK inhibitors with patients.
EP. 7: How to Explain JAK Inhibitor Warnings to Patients
Experts outline strategies for patient conversations around the black box warning.
2 Clarke Drive Cranbury, NJ 08512